TickerFacts.

Merck & Co., Inc. (MRK): Cash & Equivalents

Annual figures by period end, from SEC filings.

$14.56B
As of 2025-12-31
$6.85B
As of 2026-06-30
+4.7%
3-year compound annual growth
+12.6%
5-year compound annual growth
+5.5%
10-year compound annual growth
$15.62B2007-12-31: $5.34B2008-12-31: $4.37B2009-12-31: $9.31B2010-12-31: $10.90B2011-12-31: $13.53B2012-12-31: $13.45B2013-12-31: $15.62B2014-12-31: $7.44B2015-12-31: $8.52B2016-12-31: $6.51B2017-12-31: $6.09B2018-12-31: $7.96B2019-12-31: $9.68B2020-12-31: $8.05B2021-12-31: $8.10B2022-12-31: $12.69B2023-12-31: $6.84B2024-12-31: $13.24B2025-12-31: $14.56B$14.56B
2007-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$14.56B+10.0%2026-02-24, Balance as of period end
2024-12-31$13.24B+93.6%2026-02-24, Balance as of period end
2023-12-31$6.84B-46.1%2025-02-25, Balance as of period end
2022-12-31$12.69B+56.8%2024-02-26, Balance as of period end
2021-12-31$8.10B+0.6%2023-02-24, Balance as of period end
2020-12-31$8.05B-16.8%2022-02-25, Balance as of period end
2019-12-31$9.68B+21.5%2021-02-25, Balance as of period end
2018-12-31$7.96B+30.7%2020-02-26, Balance as of period end
2017-12-31$6.09B-6.5%2019-02-27, Balance as of period end
2016-12-31$6.51B-23.6%2018-02-27, Balance as of period end
2015-12-31$8.52B+14.6%2018-02-27, Balance as of period end
2014-12-31$7.44B-52.4%2017-02-28, Balance as of period end
2013-12-31$15.62B+16.1%2016-02-26, Balance as of period end
2012-12-31$13.45B-0.6%2015-02-27, Balance as of period end
2011-12-31$13.53B+24.1%2014-02-27, Balance as of period end
2010-12-31$10.90B+17.1%2013-02-28, Balance as of period end
2009-12-31$9.31B+113.2%2012-02-28, Balance as of period end
2008-12-31$4.37B-18.1%2011-02-28, Balance as of period end
2007-12-31$5.34Bn/a2010-03-01, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Merck & Co., Inc. (MRK)2025-12-31$14.56B+10.0%
Eli Lilly & Co (LLY)2025-12-31$7.27B+122.4%
Pfizer Inc (PFE)2025-12-31$1.14B+9.5%
AbbVie Inc. (ABBV)2025-12-31$5.23B-5.3%
Bristol Myers Squibb Co (BMY)2025-12-31$10.21B-1.3%
Johnson & Johnson (JNJ)2025-12-28$19.71B-18.2%
Abbott Laboratories (ABT)2025-12-31$8.52B+11.9%
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$3.56B+7.8%
Regeneron Pharmaceuticals, Inc. (REGN)2025-12-31$3.12B+25.3%

Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗